Puneet Souda, an analyst from Leerink Partners, reiterated the Hold rating on Twist Bioscience (TWST – Research Report). The associated price target is $48.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Puneet Souda has given his Hold rating due to a combination of factors surrounding Twist Bioscience’s recent performance and market position. The company delivered a modest beat in revenue and gross margins for FY1Q25, with revenues slightly exceeding expectations. While the SynBio and BioPharma segments saw some positive revisions in revenue guidance, there was a lack of upward guidance in the NGS segment, which is a primary growth driver for the company.
Despite the company’s impressive growth and market share gains, there are concerns about the sustainability of this outperformance amidst an uncertain sector backdrop. Additionally, competition is expected to increase, particularly in the SynBio segment, which could impact Twist Bioscience’s ability to maintain its current growth trajectory. These factors contribute to the decision to maintain a Hold rating, with the belief that current valuations already reflect the optimism around recent performance.
Based on the recent corporate insider activity of 120 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TWST in relation to earlier this year.